PBAC's latest decision on Alendronic acid: Recommended with restriction (2016). Considered for Treatment of osteoporosis in patients aged 70 years and above with a BMD T-score of -2.5 or less; corticosteroid-induced osteoporosis in patients with a BMD T-score of -1.5 or less; and established osteoporosis in patients who have had a fracture due to minimal trauma.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-neutral
no incremental cost
Submissions
3
first 2010
Submissions
3
2010 → 2016
Eligible population
Patients with osteoporosis meeting current PBS restrictions for alendronate tablets, particularly those with dysphagia or other swallowing difficulties
Therapy area
Musculo-skeletal
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Comparator
alendronate tablets
Economic model
Cost-minimisation
ICER note
Minor submission with no clinical trials presented; economic analysis not applicable as listing recommended to be cost-neutral
ICER (historical)
$15k/QALY–$45k/QALY in an earlier submission (2011) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Jul 2010: Recommended with restriction · Authority Required